Attorney Docket No. UM-13248 MAY 2 1 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

THADE!

In re Application of: Wang et al.

Serial No.:

10/594,200

Group No.:

Filed:

9/22/2006

Examiner:

Entitled: **Small Molecule Antagonists of XIAP Family Proteins**

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postar Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amandment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 17, 2007

By:

Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including references, in the above-identified application, for filing in the U.S. Parent Office.

This Information Discloyure Statement and PTO Form-1449 is being filed before the issuance of a first Office Action, therefore Applicants believe no fee is required.

The Commission is hereby authorized to charge any additional fee or chedit overpayment to our Deposit Account No. 98-1290. An originally executed duplicate of this transmittal a enclosed for this purpose.

Dated:

May 17, 2007

Robert A. Goetz

Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 305 San Francisco, California 94105 608/218-6900



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wang et al.

Serial No.: 10/594,200 Filed: 9/22/2006 Group No.: Examiner:

Entitled:

Small Molecule Antagonists of XIAP Family Proteins

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patent P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § #.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Altendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 17, 2007

Mary Ellen Waite

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- Database CAPLUS Acc. No 1963:59491, CA 58:59491, Cain BF Patential antitumor agents II. polyporic acid series', see abstract.
- Database CAPLUS Acc. No 1965:36588, Doc. No. 62:36588, Cain BF "Potential antitumor agents. III. polyporic acid', see abstract.

This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 CFR 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

Applicants' herewith submit the International Search Report for the corresponding PCT Application No. PCT/US2005/09378.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 5-17-2007

Robert A. Goetz

Registration No. 55,210

Medlen & Carroll, LLP

101 Howard Street, Suite 350

San Francisco, California 94105

608/218-6900

PTO/SB/08B (08-03)

Un	der the Paperwork Red	action A	ot of 1995, no parsons ar	Approved for use through 07/31/2006. OMB 06\$1-003 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI re required to respond to a collection of information unless it contains a valid OMB control number		
Substitu	te for form 1449/PTO		2	Complete if Known		
Substitute for form 1449/PTO AMAY 2 1 2007				Application Number	10/594,200	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	9/22/2006	
				First Named Inventor	Wang et al.	
	(Use as many she	ate ae n	arassam)	Art Unit	not assigned	
(coo do many chocas da hocassary)				Examiner Name	not assigned	
Sheet	1	of	1	Attorney Docket Number	UM 13248	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	Database CAPLUS Acc. No 1963:59491, CA 58:59491, Cain BF Potential antitumor agents II. polyporic acid series', see abstract.		
	2	Database CAPLUS Acc. No 1965:36588, Doc. No. 62:36588, Cain BF "Potential antitumor agents. III. polyporic acid', see abstract.		

Examiner	Mastin Calalal	Date	07/08/2010
Signature	/ Laotiq Solola/	Considered	07/00/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.